Quantcast
Last updated on April 20, 2014 at 14:04 EDT

Epitomics Releases New Antibodies Developed With the National Cancer Institute’s Center for Cancer Research

July 26, 2011

BURLINGAME, Calif., July 26, 2011 /PRNewswire/ — Epitomics, Inc., a biotechnology company commercializing the next generation of antibodies based on its groundbreaking Rabbit Monoclonal (RabMAb®) technology, today announced the Company has now launched 23 novel cancer-related antibodies that were developed through a partnership with the National Cancer Institute’s Center for Cancer Research. The goal of this partnership is to develop novel, high quality reagents for cancer research and make them available to the scientific community.

“We are very excited to see the progress we have made in developing several key antibodies with NCI investigators and look forward to continuing working with them to develop high quality rabbit monoclonal antibodies,” said Dr. Guo-Liang Yu, CEO, Epitomics, Inc.

All of the antibodies made under the collaboration are available for purchase in the USA directly through Epitomics and around the world through Epitomics international distributors. It is anticipated that another 20 antibodies will be developed through this partnership and released by Epitomics over the next 2 years.

Visit http://www.epitomics.com/products/nci to view the current list of antibodies released.

About Epitomics

Epitomics, Inc. is a biotechnology company dedicated to developing breakthrough monoclonal antibody technology for research and diagnostic applications. The Company’s core technology is its unique and proprietary RabMAb(R) (Rabbit Monoclonal Antibody) technology which produces antibodies with superior binding affinity and bioactivity in a wide variety of biological assays. Epitomics has also developed a proprietary method for humanizing RabMAbs called Mutation Lineage Guided (MLG) humanization. Epitomics, Inc. is headquartered in Burlingame, California, and operates a wholly owned subsidiary in Hangzhou, the People’s Republic of China. For more information about Epitomics, please visit www.epitomics.com.

SOURCE Epitomics, Inc.


Source: newswire